公开(公告)号：US20080038256A1

公开(公告)日：2008-02-14

申请号：US11626055

申请日：2007-01-23

申请人： Junho CHUNG ,  Kisu Kim

发明人： Junho CHUNG ,  Kisu Kim

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07H21/04 ,  C07K16/22 ,  C40B10/00

CPC分类号： C07K16/32 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/24 ,  A61K2300/00

摘要： The inventive anti-HGF/SF humanized antibody prepared by displaying on the surface of a phage an anti-HGF/SF chimeric Fab library comprising a set of human antibody light chain variable region (VL) and human antibody heavy chain variable region (VH) which are grafted with heavy chain complementary determining regions (HCDRs) of an anti-HGF/SF antibody of an animal other than human, has the equal or greater binding affinity than that of the parent anti-HGF/SF antibody, the neutralizing activity inhibiting the binding of HGF/SF to its receptor, cMET, while having the reduced immunogenicity in human. Therefore, the inventive anti-HGF/SF humanized antibody can be used for preventing and treating diseases effectively, e.g., cancers, by the action of binding HGF/SF to cMET.

摘要翻译： 通过在噬菌体表面上显示包含一组人抗体轻链可变区（V L L L）和人的抗HGF / SF嵌合Fab文库制备的本发明抗HGF / SF人源化抗体 用除人以外的动物的抗HGF / SF抗体的重链互补决定区（HCDR）接枝的抗体重链可变区（V H H H S）具有相等或更大的结合亲和力 与抗原HGF / SF抗体相比，中和活性抑制HGF / SF与其受体cMET的结合，同时在人体中具有降低的免疫原性。 因此，通过将HGF / SF结合到cMET的作用，本发明的抗HGF / SF人源化抗体可用于有效地预防和治疗疾病，例如癌症。

公开(公告)号：US20080226650A1

公开(公告)日：2008-09-18

申请号：US12048636

申请日：2008-03-14

申请人： Sunyoung PARK ,  Junho CHUNG ,  Dohoon LEE ,  Jae-Gahb PARK

发明人： Sunyoung PARK ,  Junho CHUNG ,  Dohoon LEE ,  Jae-Gahb PARK

IPC分类号： A61K39/395 ,  C07K16/44 ,  C07H21/00 ,  A61P25/30 ,  C12N5/00

CPC分类号： C07K16/16 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/55

摘要： The present application discloses monoclonal antibody against cotinine and nicotine.

摘要翻译： 本申请公开了针对可替宁和尼古丁的单克隆抗体。

公开(公告)号：US20100172902A1

公开(公告)日：2010-07-08

申请号：US12635392

申请日：2009-12-10

申请人： Junho CHUNG ,  Eun Kyung RYU ,  Ji Eun LEE ,  Sukmook LEE

发明人： Junho CHUNG ,  Eun Kyung RYU ,  Ji Eun LEE ,  Sukmook LEE

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61P29/00 ,  A61P37/00 ,  A61P37/06 ,  A61P9/10 ,  A61P1/00

CPC分类号： C07K16/2836 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2319/30

摘要： A method for treating a VCAM-1 mediated disease comprising administering a therapeutically effective amount of a monoclonal antibody to a patient in need thereof. The monoclonal antibody specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1). The monoclonal antibody comprises(a) a light chain CDR 1 region defined by SEQ ID NO:5, a light chain CDR 2 region defined by SEQ ID NO:6, and a light chain CDR 3 region defined by SEQ ID NO:7, and (b) a heavy chain CDR 1 region defined by SEQ ID NO:8, a heavy chain CDR 2 region defined by SEQ ID NO:.9 or 11, and a heavy chain CDR 3 region defined by SEQ ID NO:10 or 12.

摘要翻译： 一种治疗VCAM-1介导的疾病的方法，其包括向有需要的患者施用治疗有效量的单克隆抗体。 单克隆抗体特异性结合人和小鼠血管细胞粘附分子-1（VCAM-1）。 单克隆抗体包含（a）由SEQ ID NO：5定义的轻链CDR1区，由SEQ ID NO：6定义的轻链CDR2区和由SEQ ID NO：7限定的轻链CDR3区， 或（b）由SEQ ID NO：8定义的重链CDR1区域，由SEQ ID NO：.9或11定义的重链CDR2区域和由SEQ ID NO：10定义的重链CDR3区域 12。